Drug intelligence / Profile preview

GEMMi

Development stage: Preclinical
Lead developer: Artizan Biosciences
Modality: Small Molecules

Overview

GEMMi is a matrix metalloproteinase (MMP) inhibitor being developed by Artizan Biosciences in collaboration with the University Medical Center of Utrecht. It is a small molecule designed to target chronic inflammation and immune dysregulation by disrupting intestinal triggers of the inflammation process. The drug is currently in the discovery stage and is primarily being investigated for the treatment of inflammatory bowel disease (IBD). GEMMi represents a new molecular class that leverages the human gut as a drug discovery tool to identify and neutralize specific drivers of intestinal inflammation.

Targets

MMP12 (Macrophage Metalloelastase)

Beyond the preview

Go deeper on GEMMi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEMMi.

Explore the full profile